DisordersComprehensive CareResearchResourcesContact UsHome

The physicians at the Central Virginia Center for Coagulation Disorders actively publish research in their respective fields.

Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.

Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012 May;18(3):375-82. doi: 10.1111/j.1365-2516.2011.02700.x. Epub 2011 Nov 21.

Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Pelzer H, Agersø H, Carr ME, Ezban M, Hedner U. Monitoring rFVIIa 90 µg Kg-1: Comparing Laboratory Response of Using Various Whole Blood Assays Over 6 h. Haemophilia. 2011 Mar 1. doi: 10.1111/j.1365-2516.2011.02492.x. [Epub ahead of print]

Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Ezban M, Hedner U. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Blood Coagul and Fibrinolysis. 2011 Jun 15. [Epub ahead of print]

Agersø H, Brophy DF, Martin EJ, Pelzer H, Carr ME, Hedner U, Ezban M. Factor VIIa cleared principally by antithrombin following IV administration in haemophilia patients. J Thromb Haemost. 2011;9:333-8.

Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett JC, Ezban M. Factor VIIa analog (NN1731) hasmarked effects on platelet function and clot kinetics in blood from patients with hemophilia A. Blood Coagul Fibrinolysis.2010;21:539-46.

Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett, JB, Exban, M. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A. Blood Coagulation and Fibrinolysis (24 June 2010) doi: 10.1097/MBC.0b013e32833b63e9

Creary MS, Soucie JM, Miller CH, Hooper WC, Abshire TC, Brettler DB, Bockenstedt PL, DiPaola J, Massey GV, Neff AT, Shapiro, AD, Tarantino MD, Wicklund BM, DiMichele D. U.S. Inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence.

Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Carr ME. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia (Online Early Articles). doi:10.1111/j.1365-2516.2007.01524.x.

Sterling RK, Lyons CD, Stravitz RT, Luketic VA, Sanyal AJ, Carr ME, Smith TJ, Hackney MH, Contos MJ, Mills SA, Kuhn JG, Nolte ME, Shiffman ML. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia 2007 Mar; 13 (2), 164-171.

Greilich PE, Brouse CF, Beckham J, Jessen ME, Martin EJ, Carr ME. Reductions in platelet contractile force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery. Thromb Res. 2002 Mar 15;105:523-9.

Carr ME Jr, Martin EJ, Carr SL. Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Blood Coagul Fibrinolysis. 2002 Apr;13:193-7.

Carr ME Jr, Loughran TP, Cardea JA, Smith WK, Kuhn JG, Dottore MV. Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor. Int J Hematol. 2002 Jan;75:95-9.

Topaz O, Minisi AJ, Bernardo NL, McPherson RA, Martin E, Carr SL, Carr ME, Jr. Alterations of platelet aggregation kinetics with ultraviolet laser emission: the "stunned platelet" phenomenon. Thromb Haemost. 2001 Oct;86:1087-93.

Whelen S, Carr ME Jr. Use of recombinant hirudin in heparin-induced thrombocytopenia and thrombosis (HITT) and renal failure--a case report. Angiology. 2001 Oct;52:711-5.

Carr ME Jr, Carr SL, Martin EJ, Johnson BA. Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine--a case report. Angiology. 2001 May;52:361-6.

Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001 Jan-Feb;15:44-54. Review.

Greilich PE, Alving BM, Longnecker D, Carr ME Jr, Whitten CW, Chang AS, Reid TJ. Near-site monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thrombelastograph. J Cardiothorac Vasc Anesth. 1999 Feb;13:58-64.

Carr ME Jr.In vitro assessment of platelet function. Transfus Med Rev. 1997 Apr;11:106-15. Review.

Massey, GV, Kuhn, JG, Nogi J, Spottswood SE, Narla LD, Dunn NL, Russell EC. The spectrum of myositis ossificans in haemophilia Haemophilia 2004, Mar; 10 (2): 189-193.

Gabriel, DA, Carr, ME, Roberts, HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol. 2004 Jan; 41(1 Suppl): 20-4.

Carr, ME, Carr, SL, Tildon, T, Fisher, LM, Martin, EJ. Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies. Journal of Thrombosis and Haemostasis 1: 243-249, 2003.

Carr, ME, Carr, SL, Roa, V, McCardell, KA. Aprotinin counteracts heparin-induced inhibition of platelet force. Thrombosis Research 108: 161-168, 2003.

Carr, ME, Wnek, G, Simpson, D, Bowlin, GL. Electrospinning of Nanofiber Fibrinogen Structures. Nano Letters 3: 213-216, 2003.

Carr, ME. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochemistry and Biophysics 38: 55-78, 2003.

Carr, ME, Kuhn, JG, Martin, EJ, Tidwell, AR, Hagan, M.K. Pseudo-prolongation of the prothrombin time during treatment for bleeding with recombinant factor VIIa in a patient with a spontaneous Factor VIII inhibitor. International Journal of Hematology 77: 308-309, 2003.

Carr, ME, Martin, EJ, Kuhn, JG, Seremetis, SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thrombosis and Haemostasis 89: 803-11, 2003.

Carr, ME, Angchaisuksiri, P, Carr, SL, Martin, EJ. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function and clot structure in whole blood. Cell Biochemistry and Biophysics 39: 89-100, 2003.

Carr, ME, Martin, EJ, Kuhn, JG, Spiess, BD. Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). Journal of Thrombosis and Haemostasis 1: 1977-1983,2003.

Layman, JM, Kenawy, E, Watkins, JR, Carr, ME, Bowlin, G, Wnek, GE. Development of the Biohemostat – A treatment modality for high pressure bleeding based on super absorbent polymer and electrospun membranes. Polymer Preprints 44: 94-5, 2003.

Carr, ME, Krishnaswami, A, Martin, EJ. Platelet contractile force (PCF) and clot elastic modulus (CEM) are elevated in diabetic patients with chest pain. Diabetic Medicine 19:862-866, 2002.

Carr, ME, Hackney, MH, Hines, SJ, Heddinger, SP, Carr, SL, Martin, EJ. Enhanced platelet force development despite drug induced inhibition of platelet aggregation in patients with thromboangiitis obliterans. Vascular and Endovascular Surgery 36: 473-480, 2002.

Krishnaswami, A, Carr, ME, Jessie, RL, Kontos, M, Minisi, AJ, Ornato, JP, Vetrovec, GW, Martin, EJ. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thrombosis and Haemostasis 88: 739-44, 2002

VCU Health System | Central Virginia Center for Coagulation Disorders
P.O. Box 980461 | Richmond, VA | 23298-0461
phone: (804) 827-3306 | toll free: (866) 288-2516 | fax: (804) 692-0291

contact us
| acknowledgments
last updated: 02/17/2014
Central Virginia Center for Coagulation Disorders